IGC Pharma Inc SEC Filings

IGC Pharma (IGC) reported an insider equity award. A director received 500,000 stock options on 10/17/2025 with an exercise price of $0.35 per share, according to a Form 4. The award reflects equity-based compensation and was recorded as directly owned derivative securities.

The options vest equally over three years starting on March 31, 2026, and carry an expiration date of March 31, 2038. Form 4s disclose changes in insiders’ beneficial ownership; option grants like this typically do not involve immediate cash transactions and do not represent an open-market purchase or sale.

IGC Pharma (IGC) reported an insider equity award. A director was granted 500,000 stock options at an exercise price of $0.35 per share on 10/17/2025.

The options vest equally over three years starting on March 31, 2026 and expire on March 31, 2038. The filing lists the holdings as direct ownership. This reflects routine equity-based compensation and does not involve an immediate cash transaction.

IGC Pharma (IGC) filed a Form 4 reporting insider equity activity on 10/17/2025. The reporting person, a Director and PFO, made a gift of 50,000 shares of common stock. Following the transaction, beneficial ownership of common shares was 1,134,252 (direct).

The filing also reports two option grants at an exercise price of $0.35: 1,000,000 options vesting equally over three years starting March 31, 2026 (expiration 03/31/2038), and 500,000 options that vest upon achievement of Board-set milestones (expiration 03/31/2036). These awards reflect equity compensation and do not involve cash transactions at grant.

IGC Pharma (IGC) reported insider activity on a Form 4. CEO and Director Ram Mukunda was granted stock options and made a share gift on 10/17/2025.

Grants include 3,000,000 options with a $0.35 exercise price, vesting equally over three years starting March 31, 2026, and 1,500,000 options with a $0.35 exercise price that vest upon Board‑set milestones. He also reported a gift of 100,000 shares of common stock. Following these transactions, he beneficially owned 3,992,678 shares, held directly.

IGC Pharma (IGC) reported results from its 2025 Annual Meeting held on October 10, 2025. Stockholders elected Ram Mukunda and James Moran as Class C directors to serve until the 2028 annual meeting and ratified Manohar Chowdhry & Associates as the independent auditor for the 2026 fiscal year.

Shareholders approved the grant of 5,000,000 shares of common stock to be issued from time to time to employees, advisors, directors, and consultants based on board- or CEO-set performance, vesting, and incentive metrics. They also approved an amendment to increase authorized common stock from 150,000,000 to 600,000,000 shares. A non-binding advisory vote set the frequency of say-on-pay votes at every three years.

Participation was strong, with 53,776,307 shares voted, representing approximately 59.22% of the 90,809,112 shares outstanding and entitled to vote. Broker non-votes totaled 18,341,638.

IGC Pharma, Inc. prospectus supplement describes securities the company may offer and highlights capital needs and risks tied to its drug and hemp-related businesses. The company has reserved millions of shares for incentive plans, restricted stock, and unit conversions and disclosed a September 2024 share purchase agreement for 588,235 shares at a total of $200,000. The document lists primary uses of proceeds, including working capital, funding pre-clinical and clinical trials for IGC-AD1 and TGR-63, AI development to streamline trials, lab and GMP facility development, marketing, patent filings and potential acquisitions. Key risk factors include funding sufficiency, regulatory approvals (including FDA INDA and Phase 2 trials), reliance on third parties for trials and manufacturing, intellectual property protection, market acceptance of phytocannabinoid/hemp-based products, geopolitical and economic conditions across multiple regions, and data security or IT disruptions.

IGC Pharma, Inc. proxy materials disclose details of the company’s equity plans, insider trading rules, and Audit Committee review for Fiscal 2025. Equity compensation plans approved by security holders show 13,823,529 shares available, representing 15.21% (figures presented in the filing). The filing cautions that future equity issuances could dilute market price, earnings per share, and book value per share if shares are issued below market or via low conversion prices. The company states it did not grant any stock options, SARs, or similar option-like instruments in Fiscal 2025. The Insider Trading Policy applies to directors, officers, employees and is filed as Exhibit 19.1. The Audit Committee reviewed audited financial statements with management, discussed required matters and auditor independence with Manohar Chowdhry & Associates, and recommended inclusion of the audited financial statements in the Annual Report for Fiscal 2025.